Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia (AIRVM-COVID)
Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia: a Randomized Controlled Double-blind Study From the Skip-icu Consortium
Sponsor: Assistance Publique - Hôpitaux de Paris
Listed as NCT04357457, this PHASE3 trial focuses on Covid 19 and Hypoxemic Respiratory Failure and remains completed. Sponsored by Assistance Publique - Hôpitaux de Paris, it has been updated 11 times since 2020, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Nov 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE3
▶ Show 6 earlier versions
-
Jun 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Apr 2021 — Jun 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE3
-
May 2020 — Jun 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Assistance Publique - Hôpitaux de Paris
For direct contact, visit the study record on ClinicalTrials.gov .